- Home
- CKPT vs SNBR Comparison
CKPT vs SNBR Comparison
Compare CKPT & SNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- SNBR
- Stock Information
- Founded
- CKPT 2014
- SNBR 1987
- Country
- CKPT United States
- SNBR United States
- Employees
- CKPT N/A
- SNBR N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- SNBR Home Furnishings
- Sector
- CKPT Health Care
- SNBR Consumer Discretionary
- Exchange
- CKPT Nasdaq
- SNBR Nasdaq
- Market Cap
- CKPT 361.1M
- SNBR 399.8M
- IPO Year
- CKPT 2017
- SNBR 1998
- Fundamental
- Price
- CKPT $4.26
- SNBR $10.76
- Analyst Decision
- CKPT Buy
- SNBR Hold
- Analyst Count
- CKPT 3
- SNBR 2
- Target Price
- CKPT $4.33
- SNBR $9.00
- AVG Volume (30 Days)
- CKPT 2.1M
- SNBR 558.6K
- Earning Date
- CKPT 05-13-2025
- SNBR 04-30-2025
- Dividend Yield
- CKPT N/A
- SNBR N/A
- EPS Growth
- CKPT N/A
- SNBR N/A
- EPS
- CKPT N/A
- SNBR N/A
- Revenue
- CKPT $41,000.00
- SNBR $1,605,108,000.00
- Revenue This Year
- CKPT $102,182.93
- SNBR N/A
- Revenue Next Year
- CKPT $351.71
- SNBR $3.67
- P/E Ratio
- CKPT N/A
- SNBR N/A
- Revenue Growth
- CKPT N/A
- SNBR N/A
- 52 Week Low
- CKPT $1.80
- SNBR $4.48
- 52 Week High
- CKPT $4.50
- SNBR $20.75
- Technical
- Relative Strength Index (RSI)
- CKPT 80.26
- SNBR 66.63
- Support Level
- CKPT $4.14
- SNBR $8.82
- Resistance Level
- CKPT $4.20
- SNBR $9.89
- Average True Range (ATR)
- CKPT 0.03
- SNBR 0.72
- MACD
- CKPT -0.00
- SNBR 0.19
- Stochastic Oscillator
- CKPT 85.71
- SNBR 75.12
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.